Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Farlong Nutraceutical Concludes 30-Day Clinical Study to Determine Safety and Effectiveness of Farlong InnerPure® Colon Detox


News Image

Farlong’s InnerPure® Colon Detox, an all-natural health supplement blend of eight different herbal extracts

Subjects on InnerPure® lost an average of four to five pounds during the 30-day study. With constipation, it was found that 100% of subjects had a positive impact when taking InnerPure® with all subjects experiencing positive and healthy improvements in their daily bowel movements.

Farlong Nutraceutical, a vertically integrated, plant-based ingredient and supplement company, conducted a 30-day double blind, placebo-controlled safety and efficacy study with 125 healthy human subjects using InnerPure® Colon Detox to determine the effects on healthy bowel movement, weight management and acne.

Conducted by M. Montgomery PhD and E. Masters M.D., the study followed 100 subjects taking various dosages of InnerPure® supplements, and 25 subjects on placebo. During the 30-day study period, 34 subjects took one capsule twice daily, 33 took two capsules twice daily, and 33 took three capsules twice daily. The 25 subjects on placebo took one capsule twice daily for the duration of the study. On day 15 and 30, subjects were evaluated for compliance and weight, and laboratory tested for blood work.

Upon conclusion of the 30-day period, InnerPure® was shown to be safe, effective, and well tolerated with no negative impact on any organs or systems, and no interactions, sensitivities, or side effects reported during the course of the study. The most significant positive impacts were seen in relieving constipation and weight loss. Subjects on InnerPure® lost an average of four to five pounds during the 30-day study. With constipation, it was found that 100% of subjects had a positive impact when taking InnerPure® with all subjects experiencing positive and healthy improvements in their daily bowel movements.

InnerPure® Colon Detox is an all-natural blend of eight different herbal extracts that have been processed to release toxins from the body. Farlong recently initiated “Generally Recognized As Safe” (GRAS) Assessment for the plant extracts, Xiaohongshen (Radix Et Rhizonma Rubiae Yunnanensis) and Qingyangshen (Radix Cynanchi Otopylli), the active ingredients in the proprietary formula for InnerPure® Colon Detox. The formula’s many properties include the ability to promote detoxification and healthy, glowing skin; reduce acne, dark spots and pimples; improve circulation and bowel movement; and promote anti-aging. InnerPure® can be a powerful tool for managing weight, as it helps with digestion by assisting the body to better absorb nutrients from food, allowing users to eat less and still receive the energy benefits. It also enhances the metabolism which can assist in burning off fat more efficiently, especially during exercise.

Farlong’s ingredient studies:

Farlong is currently conducting a 90-day double blind, randomized, controlled, parallel study to determine the safety and effectiveness of Farlong Lifeflower® Breviscapine on improving long and short-term memory, concentration, and clarity of thinking in healthy individuals. In 2020, the company completed a three-year clinical trial in North America to determine the effects of Ginseng Plus® Panax Notoginseng™ extract, which demonstrated that Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract) supplementation was well tolerated and may have a positive influence on reducing the risk of cardiovascular disease by improving blood pressure and HDL-C. The trial results are published in a peer-reviewed medical journal, Current Nutraceuticals Journal by Bentham Science.

About Farlong Nutraceutical:

Farlong is a science-based and vertically integrated functional ingredient and formula provider who has more than 24 years of experience focusing on discovering, developing, and providing safe, effective, and unique medicinal herbs, plant extracts, and formulas with its own GAP (Good Agricultural Practice) certified cultivation base, cGMP (Current Good Manufacturing Practice) certified manufacturing facilities and distribution channels. Combining ancient Oriental medicine and modern technology, Farlong develops its own line of natural supplement brands, while offering contract manufacturing services and ingredients for health and beauty companies to create proprietary formulas and product lines. For more information, visit Farlong.com for supplements and 400+ ingredients, and follow on Facebook, Twitter and Instagram.

Share article on social media or email:



Port X Logistics Signs on as Presenting Sponsor for Ninth Annual Empire State Ride to End Cancer


“Cancer has touched the lives of everyone in some way or another, including many of the staff members at Port X Logistics. We are pleased to be donating $50,000 to the Empire State Ride and the Roswell Park Alliance Foundation, and we wish all of the Empire State Ride riders a safe and fun journey.”

Thanks to the success of the 2022 event, where more than 200 riders crossed New York State by bike to support the fight to end cancer, Port X Logistics has signed on as presenting sponsor for the ninth annual Empire State Ride. The Empire State Ride takes hundreds of cyclists 500+ miles across New York State to raise funds and awareness for cancer research and clinical trials at Roswell Park Comprehensive Cancer Center.

“Port X Logistics has been very fortunate to grow at a rapid pace in our five-year existence,” says Brian Kempisty, founder of Port X Logistics. “This is why we’re able to give back to our community, especially to Roswell Park Comprehensive Cancer Center and the Empire State Ride. Cancer has touched the lives of everyone in some way or another, including many of the staff members at Port X Logistics. We are pleased to be donating $50,000 to the Empire State Ride and the Roswell Park Alliance Foundation, and we wish all of the Empire State Ride riders a safe and fun journey.”

“Port X Logistics is an organization that really cares about the Western New York community. Their support of Empire State Ride is the perfect example of that, and we’re thrilled to have them on board for the second year in a row. Together, we look forward to making an even bigger impact in the fight to end cancer,” said Terry Bourgeois, founder of Empire State Ride.

Registration for the weeklong event is now open with a reduced registration fee of $100 through the end of the year. Riders commit to raising $3,500 to benefit cutting-edge research and clinical trials at Roswell Park Comprehensive Cancer Center.

To learn more about the event, visit http://www.empirestateride.com.

Please direct all media inquiries to James Byrne at jamesb@portxlogistics.com or 716-706 9770.

About Port X Logistics

Port X Logistics specializes in expediting containerized cargo throughout the US and Canada. Our combination of company trucks, owner operators, and logistics network allows us to effectively service every port and rail ramp. Port X Logistics provides drayage, trans-loading, and over-the-road trucking, as well as intermodal drayage of containers to and from the rail to help our clients meet their fulfillment and production plans. We operate with urgency, attention to detail, proactive communication, and the ultimate in visibility.

About Roswell Park Comprehensive Cancer Center

Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at RoswellPark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@roswellpark.org.

Share article on social media or email:

Elevating the Human Experience through Generosity and Connection


“Volunteers carry great responsibility as a critical contact point for those engaging in healthcare” – Stacy Palmer, Senior Vice President and COO

The Beryl Institute releases “The Evolving Role of Healthcare Volunteer Programs:

Elevating the Human Experience through Generosity and Connection,” identifying how volunteers are transforming healthcare by impacting eight critical areas of patient experience. The paper highlights perspectives from both volunteer leadership and the volunteers themselves on the value and means in which volunteers are strategically deployed, including how they are recruited, developed, evaluated and supported.

The paper points to data from the most recent edition of PX Pulse which revealed consumers feel quality and experience in healthcare are trending downward. The report highlights how the evolving role of volunteer programs may address the course of consumer perspective and provides strategies every healthcare organization should consider.

Key takeaways include:


  • Volunteers must be regarded as essential workers and treated in the same way as staff to maximize their impact.
  • Volunteers bring a spectrum of talent and gifts to their vocation, so they should be deployed strategically.
  • Volunteers can impact quality and excellence of care, highlighting the importance of building and developing volunteer programs.

“Volunteers carry great responsibility as a critical contact point for those engaging in healthcare,” said Stacy Palmer, Senior Vice President and Chief Operating Officer of The Beryl Institute. “They help fill the needs of organizations in expanding capacity in a lean operating world. To access the executive brief, PX paper, and patient reflection visit https://www.theberylinstitute.org/page/PXPapers

###

About The Beryl Institute

The Beryl Institute is a global community of healthcare professionals and experience champions committed to transforming the human experience in healthcare. As a pioneer and leader of the experience movement and patient experience profession for more than a decade, the Institute offers unparalleled access to unbiased research and proven practices, networking and professional development opportunities and a safe, neutral space to exchange ideas and learn from others.

We define the patient experience as the sum of all interactions, shaped by an organization’s culture, that influence patient perceptions across the continuum of care. We believe human experience is grounded in the experiences of patients and families, members of the healthcare workforce and the communities they serve.

Share article on social media or email:

Referah CEO Discusses Relationship Building Between Seniors and Senior Living Communities


Text logo spelling Referah: health home happiness in blue except the letter h in orange.

Referah: Our mission is to create relationships, not just leads.

There are points along the life of any service business history where something happened that changed the experience for the betterment of all. Referah is the game changing moment in time for senior living. Lesley Durkan, CEO, President, Referah, LLC

“Entering the senior living business wasn’t as much a daring choice as it was a continuation of a relationship I had been around since I was a teen,” explained Lesley Durkan, CEO and President of newly launched Referah, an online referral source for senior living. “My family, in one form or another, was involved either on the medical or the operational side of the industry so the familiarity was well-established. I experienced, firsthand, many of the roadblocks in senior living impacting the consumers and providers. So I did what anyone seeking improvement and innovation would and I jumped in with both feet.” That was 20+ years ago and the result of those decades of learning, according to Durkan, is what inspired this new company. Referah is positioned to set new levels of creativity and ease-of-use for the ever-growing numbers of people who are in need of, or providing, quality senior care.

For the consumer who is seeking Senior Living options for themselves or for a family member, Referah’s strength is simplifying the cumbersome process of gathering information in a world that has many new concepts, terms, conditions, and questions. “Our goal is to be more of a friend who has their best interest at heart—because we do,” expressed Durkan. “We help them navigate the process by only connecting them with the top communities that best match their need. While we’ve stated that Referah uses a concept that’s not unlike a dating app, we also provide an incredible amount of depth in background information and explanations about Senior Living.”

As for Senior Living operators, Durkan has witnessed—as have all key Referah team members—the elements that generate the most frustration. From the services which can overwhelm families with information and calls before they even talk with a community to providing unqualified matches that waste the time of the sales teams and families. “We’ve engineered a system that’s going to bring senior living communities leads that are well-matched to the levels of service they individually provide. Our goal of creating relationships, not just leads, is hard-wired in everything we do. Find me an operator who says their biggest hurdle in the business is fighting wasted time and I’ll show you someone who isn’t maximizing all of its elements to bring maximum efficiency to not only their staff, but to the bottom line,” shared Durkan.

Referah’s development over the past two years is deep in research for both sides, and the service being provided to the public at no cost, and to operators at a significant savings in comparison to leading competitors, is revolutionary. Plus, with the rising number of new families in need of assistance, Referah’s timing is perfect.

“There are points along the life of any service business history where something happened that changed the experience for the betterment of all. We think we’re at that inflection point for the senior living community business. Referah is the game changing moment in time,” concluded Durkan.

About Referah

Referah is an online marketplace, funded exclusively by investors from within the senior living industry, and backed by the most modern search tools, connecting families with senior living communities. The heart of Referah is a dedicated team of individuals committed to finding the best solution for the families and communities we serve. With a foundation built upon transparency, experience, knowledge, and relationships, it is our mission to provide seniors with unparalleled support, giving them the resources to gain life-changing experiences.

Share article on social media or email:

AIO|OCLI Vision is delighted to announce the addition of the talented Bhumi Kinariwala MD, a Fellowship-trained Refractive Surgeon


“I am thrilled to offer my refractive services to patients and be able to give them the best quality eye care that they deserve. It is also an honor to work with the innovative and talented providers on the AIO|OCLI Vision team,” stated Dr. Bhumi Kinariwala, MD.

AIO|OCLI Vision is a leading ophthalmology practice whose growth is supported by the management and administrative services of Spectrum Vision Partners (SVP), an organization serving many of the top ophthalmology groups and ambulatory eye surgery centers in New York, New Jersey, Connecticut, Pennsylvania, and West Virginia.

Dr. Kinariwala received her Doctor of Medicine degree from Sidney Kimmel Medical College at Thomas Jefferson University and a Bachelor of Science degree from Pennsylvania State University.

During completion of her ophthalmology residency at Sidney Kimmel Medical College at Thomas Jefferson University, Dr. Kinariwala has received many different awards and honors, including Pre-Clinical Honors and Clinical Honors. She was also a part of the Hobart Amory Hare Medical Honor Society. Dr. Kinariwala completed her Refractive Surgery Fellowship at Brinton Vision in St. Louis, MO.

About OCLI Vision

Founded in 1997, OCLI Vision (http://www.ocli.net) is one of the leading ophthalmology practices in the United States. The practices of OCLI Vision offer eye care services at locations throughout Connecticut, New Jersey, New York, Pennsylvania and West Virginia. OCLI Vision is led by a large group of highly skilled ophthalmologists and optometrists in each major sub-specialty of eye care who provide comprehensive eye care services, including treatment for cataracts, corneal disease, glaucoma, retinal disease, oculoplastics, refractive surgery, and neuro-ophthalmology.

About Spectrum Vision Partners

Spectrum Vision Partners (SVP) (http://www.spectrumvisionpartners.com) is a leading management services organization, serving the ophthalmology sector. With nearly 1,300 employees providing world-class practice management and administrative solutions to a network of nationally renowned, multi-specialty ophthalmologists in New York, New Jersey, Connecticut, Pennsylvania and West Virginia, SVP supports over 40 clinic locations, five state-licensed ambulatory surgery centers, and over 110 surgeons, doctors and other medical professionals. SVP provides a comprehensive set of business support functions, including billing and collections, credential services, marketing, physician recruitment, ASC development, financial and accounting services, benefits and payroll management and information technology. The company’s corporate service center is located at 825 East Gate Boulevard, Suite 111, Garden City, NY 11530.

Share article on social media or email:

Disadvantaged students pay a price to move up, says education prize winner


Photo by Brooke Sietinsons

Jennifer Morton has been named the 2023 winner of the Grawemeyer Award in Education. (Photo by Brooke Sietinsons)

By focusing on the dilemmas first-generation and low-income students can face when pursuing a degree, Morton shed light on an important but often neglected issue. She also offers strategies that colleges, faculty and students themselves can use to navigate these challenges.

Disadvantaged college students pay a heavy ethical and emotional price to become upwardly mobile, says a scholar who on Dec. 8 was named winner of the 2023 University of Louisville Grawemeyer Award in Education.

Jennifer Morton, an associate professor of philosophy at the University of Pennsylvania, earned the prize for her ideas in “Moving Up without Losing Your Way: The Ethical Costs of Upward Mobility.” Princeton University Press published the book in 2019.

The dream of achieving success by attending college is deeply flawed for some, says Morton, a first-generation college student who left Peru to attend Princeton. Drawing on her own experience, philosophical and social science research and interviews with first-generation, low-income and immigrant students, she found that the college experience often forces students to turn away from family and friends to achieve academic success.

For example, one student caring for an ill sister told Morton she had missed so many classes and assignment due dates she wasn’t sure she could catch up. Another student said he had cut ties with his community to be able to manage college.

“First-generation students are often putting their relationships with friends, family and their communities on the line,” Morton said. “We need to recognize their sacrifices and focus on the social, emotional and ethical aspects of their college experience, not simply on grade-point averages and graduation rates.”

Morton, who also is a senior fellow at the University of Wisconsin’s Center for Ethics and Education, has worked at the University of North Carolina-Chapel Hill, City College of New York and Swarthmore College. She has a doctor of philosophy degree from Stanford University and has received several awards, including the American Philosophical Association’s Scheffler Prize.

“By focusing on the dilemmas first-generation and low-income students can face when pursuing a degree, Morton shed light on an important but often neglected issue,” said Jeff Valentine, education award director. “She also offers strategies that colleges, faculty and students themselves can use to navigate these challenges.”

Recipients of next year’s Grawemeyer Awards are being named Dec. 5-9 pending formal approval by trustees. The annual, $100,000 prizes also honor seminal ideas in music, world order, psychology and religion. Winners will visit Louisville in the spring to accept their awards and give free talks on their winning ideas.

Share article on social media or email:

Torigen Pharmaceuticals and VerticalVet Enter into Preferred Partnership


News Image

Torigen Pharmaceuticals, Inc (Farmington, CT), an animal health biologics company, announced today that they have entered into a Preferred Partnership Agreement with VerticalVet, LLC(Cornelius, NC) to provide their 2,000+ clinic Group Purchasing Organization with access to Torigen. VerticalVet provides independent veterinary owners, practice managers, and technicians access to customized best practices education, real-time data insights, simplified marketing automation, and tailored partner solutions, such as Torigen’s Experimental Autologous Prescription Product.

This partnership will expand Torigen’s ability to deliver innovative companion animal cancer treatments to a larger patient population. Torigen offers experimental autologous cancer immunotherapy created from a surgically resected portion of tumor tissue that can be administered by both General Practitioners and Veterinary Oncologists. The combination of Torigen’s innovative products and VerticalVet’s vast network will allow more clinicians to be part of the veterinary oncology solution and provide more cancer treatment options to fight this devastating diagnosis.

“We are excited to partner with VerticalVet’s 2,000 veterinary hospitals nationwide,” says Ashley Kalinauskas, CEO and Co-Founder of Torigen Pharmaceuticals. “We believe that Torigen’s innovative cancer therapeutics and our diagnostic partnerships can provide more affordable and accessible treatment options to companion animal cancer patients.”

Every year, nearly ten million companion animals are diagnosed with cancer. Only 1 in 10 pet parents seek a consultation with a veterinary oncologist after receiving a cancer diagnosis from their family veterinarian. This partnership will make cancer treatments for tumor-based cancers more readily available to pet parents across the United States. Torigen’s mission is to empower veterinarians to be part of the solution through partnership and collaboration early in the diagnosis process. This is achieved by harnessing the power of the immune system to advance veterinary medicine.

“At VerticalVet, our aim is to connect our independent veterinary practice members with the best growth companies and pricing in the industry,” says John Wagoner, CEO and co-founder VerticalVet. “We are excited to finalize a partnership with Torigen and look forward to supporting their journey and continued success.”

“We’re excited to bring the latest in precision cancer treatments to our veterinary clinics,” added Ernie Ward, Chief Veterinary Officer, VerticalVet. “Our partnership with Torigen provides VerticalVet members access to individualized cancer therapy that promises to change the way veterinarians treat cancer.”

About Torigen’s Autologous Cancer Vaccine:

Torigen produces a personalized autologous prescription product for dogs, cats, and horses that uses the animal’s own tumor cells to create immunotherapy from a surgically resected portion of a tumor that can be used alone or in combination with chemotherapy and radiation. Torigen’s autologous prescription product is an experimental product regulated by the USDA Center of Veterinary Biologics under 9 CFR 103.3.

Torigen’s autologous prescription product is an active immunotherapy consisting of cells harvested from the patient’s own tumor. This whole-cell tumor vaccine is generated by a patented method to preserve cellular material and tumor- associated antigens and then mixed with immune-stimulating adjuvants. The objective is to increase the activation of tumor-specific T-cells resulting in an enhanced ability of the pet’s immune system to destroy cancer cells, stop or slow the growth of cancer cells, or delay cancer metastasis.

About Torigen Pharmaceuticals Inc:

Torigen is transforming pet cancer treatment by harnessing the pet’s immune system to create personalized cancer immunotherapies, making pet cancer treatment more accessible and more affordable. Torigen recognizes the instrumental role pets play in our families and is determined to extend the lives of companion animals despite a cancer diagnosis. With over 50% of all dogs over the age of 10 dying from cancer, Torigen is dedicated to providing affordable and effective cancer care solutions for all companion animals. Torigen is a spin-out from the University of Notre Dame and backed by Werth Family Investment Associates, Connecticut Innovations, Emerald Development Managers, Ironwood Capital, Advantage Capital, The University of Connecticut, The University of Notre Dame, SoGal Ventures, Gaingels, and other prominent investors. For more information visit http://www.torigen.com.

About VerticalVet:

Started by industry veterans with practice, industry, distribution, and manufacturing

experience, Dr. Hank Swartz and John Wagoner joined forces to vertically align all of the tools and resources clinics would need under one roof. However, the goal was never to be “just another discount club.” VerticalVet is a Group Resource Community (GRC). We provide independent veterinary owners, practice managers, and technicians access to customized best practices education, real-time data insights, simplified marketing automation, and tailored partner solutions. The VerticalVet community is diverse, inclusive, and focused on building a better normal together, allowing members to have the peace of mind to focus on what matters most: providing excellent patient care. We didn’t stop there! In 2022, VerticalVet joined forces with Vimians Group, Veterinary Services segment, VetFamily! Together, VerticalVet is now part of a global and diversified group of innovation-driven companies with a shared passion for making a positive impact through improving animal health.

Share article on social media or email:

Son’s Kidney Donation to Mom Marks 100th Kidney Transplant Performed this Year at Memorial Transplant Institute


Son waves to mom as they begin their journey to a kidney donation and transplantation at Memorial Transplant Institute

“It’s always a great day when a patient who has been on dialysis for 12 years receives a kidney,” said Dr. Ghasemian, chief, Abdominal Transplant. “A living donor transplant affords a significant advantage, as these tend to have fewer complications and on average last nearly twice as long.”

“I got tired of seeing her suffer, so I asked them if I could take a test,” said Justin, 43, who was a perfect match for his mom, Magdalena, 62. After 12 years on dialysis and various transplant denials, Magdalena and Justin’s living donor kidney transplantation surgeries took place in late October. This transplant marked Memorial Transplant Institute’s 100th kidney transplant performed within 2022.

Magdalena, who was born with polycystic kidneys, felt dialysis was “like a prison sentence.” She underwent multiple surgeries to try to save her kidneys and ultimately ended up on dialysis in 2009. In 2010, her social worker tried to get Magdalena on the kidney transplant list yet failed. After more than a decade on dialysis, and nearly giving up hope, everything changed in 2022 when Memorial received her petition and Magdalena received the call that changed her life.

“It’s always a great day when a patient who has been on dialysis for 12 years receives a kidney,” said Dr. Seyed Ghasemian, chief of Abdominal Transplant, Memorial Healthcare System. “A living donor transplant affords a significant advantage over a deceased donor kidney transplant, as these transplants tend to have fewer complications and on average last nearly twice as long.”

Having a robust living-donor transplant program speaks to the expertise of Memorial’s kidney transplant team, which includes nationally recognized physicians in transplant surgery and nephrology. Dr. Ghasemian and Nephrologist Dr. Basit Javaid each have more 30 years of experience, with Ghasemian having personally performed more than 1,000 kidney transplantations and Javaid facilitating kidney transplantation with excellent post-transplant outcomes for patients with chronic and end stage kidney disease.

Memorial’s Kidney Transplant Program is experiencing exponential growth, more than tripling the number of lives saved from 2021 to 2022. Clinical experts credit the combination of an experienced medical and surgical team that performs innovative, complex kidney transplants, coupled with the philosophy of seeing every organ as a potential chance at life, and accepting recipients who others consider “high risk.” Due to this unique approach to kidney transplantation, the program has achieved one of the shortest “time to transplant” (12 months) and one of the highest transplant rates in Florida, according to the Scientific Registry of Transplant Recipients.

“Memorial’s kidney transplant team is committed to ensuring the safety of our patients as we are coordinating life-saving transplants with positive outcomes,” said Dr. Javaid, chief of Abdominal Transplant Medicine, Memorial Healthcare System. “We are not turning patients or suitable organs away, and our expert team of physicians, practitioners, nurses, and support staff are addressing the disparities in organ availability by utilizing as many different methods of transplantation as possible.”

Aside from living donor transplantation, Memorial’s Kidney Transplant Program offers all kidney transplant options available at other nationally recognized transplant centers, including immunologically incompatible transplants, blood type incompatible transplants, and kidney transplants from donors who have hepatitis C to recipients who do not.

“Memorial is proud to be one of four transplant centers in Florida, and one of approximately a hundred such centers in the country, working with the National Kidney Registry, a nonprofit that offers a variety of living donation programs, including paired donations, also known as “kidney swap, where a living kidney donor and their incompatible recipient enter a national database and swap kidneys with a donor who is compatible with the recipient,” said Dr. Linda Chen, surgical director, Living Donor and Pediatric Abdominal Transplant Program, Memorial Healthcare System.

These physicians lead a multi-disciplinary team approach to total kidney care provided by medical and surgical transplantation experts that offer highly coordinated, customized care before, during and after surgery. The team includes surgeons, nephrologists, infectious disease specialists, pathologists, nurse practitioners, coordinators, pharmacists, social workers, dieticians, finance coordinators, living donor advocates, intensive care experts, anesthesiologists, psychologists, and cardiologists, among others.

Since the Kidney Transplant Program began in 2017, 257 patients have received life-saving kidney transplants. Most recently, the program has received referrals from all over the country and has transplanted two patients from out of state.

About Memorial Transplant Institute

Memorial Transplant Institute, based at Memorial Regional Hospital and including Joe DiMaggio Children’s Hospital, is one of only two programs in South Florida to offer adult and pediatric heart and kidney transplants. Over the past decade, Memorial Healthcare System received three federal approvals from UNOS (United Network for Organ Sharing), authorizing Joe DiMaggio Children’s Hospital to launch its pediatric heart transplant program in 2010, followed by the adult heart transplant program under Memorial Cardiac and Vascular Institute in 2014, and the adult and pediatric kidney transplant program in 2017. For more information about transplantation or donation, call 954-265-7450 or visit MHS.net/Kidney.

# # #

Dentons Global Advisors-ASG and MITRE to Sponsor ACRES Health-Science System Design Initiative at the National Academy of Medicine


News Image

Greg Koski, PhD, MD notes “ACRES, together with our partner organizations, FasterCures and MITRE, have launched an initiative to change the way we think about health and science in a more systematic way, and our sponsors, Dentons Global Advisors-ASG and MITRE, are making it possible.”

The Alliance for Clinical Research Excellence and Safety (ACRES) announced today that Dentons Global Advisors-Albright Stonebridge Group (ASG) and MITRE are sponsoring SYNERGY 2022, a unique exercise to envision a comprehensive integrated system for the future-state of health and science through application of systems-thinking and systems engineering principles.

ACRES president and founder Greg Koski, PhD, MD expressed gratitude for the support, noting, “our current approach to health has failed to efficiently and equitably provide safe, effective, evidence-based care, prevention and treatment because there is no true system to support integrated health. ACRES, together with our partner organizations, FasterCures and MITRE, have launched an initiative to change the way we think about health and science in a more systematic way, and our sponsors, Dentons Global Advisors-ASG and MITRE, are making it possible.”

The SYNERGY 2022 event, being hosted by the National Academy of Medicine, was previously announced by ACRES last month. The event convenes on December 12-13 at the National Academy of Sciences, Engineering and Medicine in Washington, DC. It brings together leaders and innovators from health, business, government, technology, academia, and patient groups to apply systems-thinking and systems engineering principles to envision a new integrated approach to health and science. The ultimate goal is to create an achievable vision of an interconnected enterprise-wide health-system that uses technology and analytics to achieve levels of quality, safety, efficiency, effectiveness and equity of access that have not previously been possible.

Dentons Global Advisors is an expert-driven advisory firm that provides integrated solutions for clients in an increasingly complex, regulated and interconnected business environment with a steadfast commitment to quality, shared values and the highest ethical standards. Comprising Albright Stonebridge Group and a deep bench of communications and strategy consultants, the firm helps clients throughout critical moments of change, challenge, or opportunity. Its Health practice – with a global team including former senior health care executives, physicians, public health leaders, medical educators, and health technology experts – supports healthcare leaders in realizing transformative growth and impact around the world.

Mehul Mehta MD, Principal at Dentons Global Advisors-ASG and lead of the Health practice, said: “The COVID pandemic has brought home the lesson that we need to bring science to the bedside much faster – we owe this to our patients and society at large. To achieve this, we need dynamic health systems with built-in ‘system intelligence’. We are proud to support this important meeting, convening all the key stakeholders, to discuss this critical issue and outline possible solutions.”

SYNERGY 2022 is also sponsored by MITRE, a not-for-profit technology company working in the public interest. As a not-for-profit organization, MITRE bridges a gap between government and industry, tackling complex challenges with no commercial interest. MITRE works in areas as diverse as artificial intelligence, data science, quantum computing, health informatics, space security, policy and economics, and cyber-resilience.

MITRE operates the Health federally-funded research and development center (Health FFRDC) for the Centers for Medicare & Medicaid Services (CMS) and the Department of Health and Human Services. Kim Warren, MITRE’s vice president and director of the CMS Alliance to Modernize Healthcare (Health FFRDC), directs MITRE’s collaboration with nonprofits, academia, and industry to achieve data-driven innovation in healthcare, public and population health, and social services. As an example, MITRE is fighting deadly diseases with equitable and accessible data with the mCODE initiative to make more and better data available to fight cancer.

Warren enthusiastically endorsed MITRE’s participation in and sponsorship of SYNERGY 2022 saying, “Applying comprehensive systems thinking and engineering approaches to our health system is a bold and much needed initiative, one that is overdue. The scope and complexity of this endeavor are massive and daunting and MITRE is delighted to offer both its engagement and its support.”

ACRES Interim Chief Executive Officer and Board of Directors chairperson, Pamela Duffy also expressed appreciation for the support of SYNERGY 2022 from Dentons Global Advisors-ASG and MITRE. “As ACRES expands its efforts to apply systems-thinking to global health and research challenges, working to promote health and access for all to safe, effective and affordable evidenced-based care, it needs ongoing support from like minded people and organizations. We are very grateful for the support that both sponsors have dedicated to this effort.”

______________________________

For further information, contact mtobin(at)acresglobal(dot)net

Share article on social media or email:

CIRCULOGENE Announces Appointment of Bob Gasparini to Board of Directors


We are thrilled to bring such a seasoned cancer diagnostics executive to our board,” said CIRCULOGENE President and CEO Mike Mullen. “With several new projects slated to be unveiled in the near future, Bob’s expertise and stellar track record will be instrumental in taking us to the next level.

CIRCULOGENE is an innovative liquid biopsy company transforming precision medicine through the rapid and cost-effective delivery of actionable results and the only laboratory in the world that reports levels of the immunotherapy biomarker PD-L1 with a simple blood test. CIRCULOGENE is proud to announce the appointment of Robert “Bob” Gasparini, M.H.S., M.S., CG(ASCP), DLM(ASCP), to its Board of Directors. Prior to his retirement in 2021, Mr. Gasparini was a medical laboratory executive for over 20 years with proven success building multi-site laboratory infrastructure, troubleshooting technical issues across multiple testing platforms, and developing corporate-wide staff and client training programs. His specialized cancer testing expertise includes a focus in Cytogenetics and Fluorescence In-situ Hybridization (FISH).

At NeoGenomics, where he served for almost 18 years, Mr. Gasparini served as President, Chief Science Officer, and was on the Board of Directors. Over this time, he was instrumental in building high complexity specialized cancer testing laboratories and implementing cost-effective testing algorithms to improve patient care and provide cost savings for institutions and the US healthcare system. In addition, Mr. Gasparini was a driver in the development of NeoUniversity, the company’s educational infrastructure for internal team members and pathology clients.

Previously in his distinguished career, he was the Director of the Genetics Division for US Labs, the Molecular Marketing Manager for Ventana Medical Systems, and the Assistant Director of the Cytogenetics Laboratory for the Prenatal Diagnostic Center, an affiliate of Mass General Hospital. While at the Prenatal Diagnostic Center, Mr. Gasparini was also an Adjunct Professor at Harvard University. He is a licensed Clinical Laboratory Director and an accomplished author in the fields of Cytogenetics and Fluorescence In-Situ Hybridization (FISH) testing.

“We are thrilled to bring such a seasoned cancer diagnostics executive to our board,” said CIRCULOGENE President and CEO Mike Mullen. “With several new projects slated to be unveiled in the near future, Bob’s expertise and stellar track record will be instrumental in taking us to the next level.”

“I am excited to be working with such an innovative and forward-thinking company,” said Mr. Gasparini. “CIRCULOGENE’s processing of liquid biopsies has streamlined the collection process and reduced the time to therapy in a significant way, making a real difference for patients facing a cancer diagnosis.”

About CIRCULOGENE

CIRCULOGENE provides comprehensive biomarker testing for a broad range of cancers allowing physicians to match patient results with specific therapies in just one week. The company has developed proprietary enrichment technology resulting in minimal genetic data loss. Their sequencing and qPCR methods can provide a full genomic load analysis to help clinicians select targeted therapies, monitor efficacy, and assess recurrence for cancer patients. Applying their proprietary liquid biopsy innovation for cfDNA and cfRNA, including PD-L1 and MSI detection, CIRCULOGENE can detect circulating germline and somatic mutations and RNA fusions.

CIRCULOGENE is a Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP) certified laboratory and a Verified Vendor for the federal System for Award Management. For more information, visit our website at circulogene.com, connect with us on LinkedIn, Facebook, and Twitter, email info@circulogene.com, or call us at 855-614-7083. Clinicians interested in ordering tests may also visit our contact page at circulogene.com/contact.

Share article on social media or email: